Skip to main content
. Author manuscript; available in PMC: 2013 Feb 20.
Published in final edited form as: J Alzheimers Dis. 2012;31(2):301–313. doi: 10.3233/JAD-2012-120598

Fig. 2.

Fig. 2

Validation of plasma MCP-1 content as a clinically accessible TBI biomarker in two demographically distinct TBI study cohorts. An independent, quantitative ELISA assay was used to assess plasma MCP-1 contents in TBI and control cases from a civilian and a military veteran study cohort. (A) Plasma MCP-1 contents in TBI (n = 14) and control (n = 10) cases from the civilian study cohort (Table 1). (B) Plasma MCP-1 contents among veteran TBI (n = 20) and control (n = 20) cases (Table 2). Scatter graphs represent values for individual cases and group mean values ± SEM of plasma biomarker contents, expressed as % of controls. *p < 0.05 by student t-test, TBI compared to the control group.